Method for producing inhibitor of activated blood coagulation factor x (fxa)
US-2017050983-A1 · Feb 23, 2017 · US
Processes for the preparation of edoxaban and intermediates thereof
US10301322B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10301322-B2 |
| Application number | US-201715850882-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2017 |
| Priority date | Dec 27, 2016 |
| Publication date | May 28, 2019 |
| Grant date | May 28, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of Formula (9-A): wherein R 2 is selected from the group consisting of an aliphatic group, substituted aliphatic group, aryl, substituted aryl, arylalkyl, and substituted arylalkyl; wherein the aliphatic group is an alkyl group selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, sec-butyl, hexanyl, 2-methyl-2-hexanyl, cyclohexyl, 1-methylcyclohexyl, cyclopropylmethyl, and isomers of n-pentyl, n-hexyl, n-heptyl, and n-octyl; and wherein substituted refers to the replacement of one or more hydrogen atoms with a substituent selected from the group consisting of R′″, OR″, NR″R″, SR″, halogen, SiR′″R′″R′″, OCOR′″, COR″, CO 2 R″, CONR″R″, NR″CO 2 R′″, NR″COR′″, SOR′″, SO 2 R′″, CN, NO 2 and CF 3 ; R″ is selected, independently, from the group consisting of hydrogen, an aliphatic group, aryl and arylalkyl; and R′″ is selected, independently, from the group consisting of an aliphatic group, aryl and arylalkyl. 2. The compound of claim 1 , wherein R 2 is an aliphatic group or a substituted aliphatic group. 3. The compound of claim 2 , selected from the group consisting of:
Assignees
Inventors
Classifications
- C07D513/04Primary
Ortho-condensed systems · CPC title
with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring · CPC title
The ring being saturated · CPC title
comprising a heterocyclic ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10301322B2 cover?
- The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.
- Who is the assignee on this patent?
- Apotex Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).